The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples